Heterozygous mutations in the GATA3 gene, encoding a transcription factor crucial for breast development, occur in 15% of estrogen receptor-positive (ER+), or luminal-type, breast cancers [1, 2]. This evidence concerns the gene GATA3 and breast carcinoma.